Introduction
The phosphoinositide 3-kinase (PI3-K) signaling pathway, one of the downstream signaling pathways activated upon stimulation of the epidermal growth factor (EGF) receptor, plays an important role in regulating cell proliferation and cell survival, and is a major driving force for human cancers (Fry, 2001; Lu et al., 2003) . Activation of PI3-K results in increased levels of phosphatidylinositol 3,4-bisphosphate (PIP2) and phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP2 and PIP3 in turn recruit Akt, a pleckstrin homology domain-containing protein, to the proximity of cell membrane, where Akt undergoes conformational changes and is subsequently phosphorylated and activated. Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) , also called mutated in multiple advanced cancers (MMAC1) (Steck et al., 1997) or transforming growth factor b-regulated and epithelial cell-enriched phosphatase (TEP1) (Li and Sun, 1997) , antagonizes the actions of PI3-K by removing the D-3 phosphate of PIP2 and PIP3 Steck et al., 1997) . Thus, PTEN is an important negative regulator of Akt activation (Li et al., 1998; Stambolic et al., 1998; Wu et al., 1998; Sun et al., 1999) . PTEN is mutated or deleted in a substantial number of cancers, including glioblastomas and cancers of the breast, prostate, and ovary, as well as several syndromes characterized by the formation of multiple tumors (Teng et al., 1997; Podsypanina et al., 1999) . Cells with PTEN mutation or deletion often exhibit a constitutive PI3-K activity and have been shown to be less sensitive to the EGF receptor tyrosine inhibitor gefitinib, compared with the counterpart cells that express wild-type PTEN (Bianco et al., 2003; She et al., 2003) .
Perifosine (octadecyl-[1,1-dimethyl-4-piperidyl]-phosphate; D-21266 or NSC639966) is a new synthetic, orally active analog of miltefosine (hexadecylphosphocholine; Miltex) (Hilgard et al., 1993 (Hilgard et al., , 1997 ; miltefosine is the prototype of a heterogeneous group of compounds called alkylphospholipids. Alkylphospholipids have potent antiproliferative and apoptosis-inducing activity against several types of in vitro and in vivo human tumor models (Hilgard et al., 1997) . Miltefosine was the first alkylphospholipid to undergo clinical evaluation and was found to have clinical antitumor activity (Verweij et al., 1992 (Verweij et al., , 1993 . Unlike other conventional chemotherapeutic agents that target DNA or RNA, alkylphospholipids primarily act on the cell membrane, making side effects such as myelosuppression and alopecia less common. However, miltefosine was found to have severe dose-related gastrointestinal toxicity and hemolytic side effects when administered parenterally; thus, it was approved only for topical use in treatments for skin metastasis from breast cancer (Unger et al., 1992; Clive and Leonard, 1997; Clive et al., 1999; Terwogt et al., 1999) and cutaneous lymphoma (Dummer et al., 1992) . Perifosine is a new derivative of the alkylphospholipids that is orally active and more tolerable than miltefosine (Hilgard et al., 1997) ; it is currently being tested in phase 1 and 2 clinical trials in patients with sarcoma and cancers of the head and neck, breast, prostate, and pancreas (Crul et al., 2002; Van Ummersen et al., 2004) .
Although the antitumor mechanism and targets of the alkylphospholipids remain to be fully elucidated, several studies have shown that, through interference with the turnover and biosynthesis of natural phospholipids, including lipid second messengers, alkylphospholipids disrupt the cell signaling network at several sites, leading to the inhibition of the PI3-K/Akt survival pathway (Kondapaka et al., 2003; Ruiter et al., 2003) , the inhibition of mitogen-activated protein kinase (MAPK) (Zhou et al., 1996; Ruiter et al., 1999) , and activation of the stress-activated protein kinase (SAPK)/ c-jun NH 2 -terminal kinase (JNK) pathway (Ruiter et al., 1999) . We propose that the effects of alkylphospholipids on these signaling pathways, particularly inhibition of the PI3-K/Akt pathway, may provide an opportunity to improve the response of PTEN-deficient cancer cells to the EGF receptor-targeted cancer therapeutics.
Cetuximab (C225; Erbitux) is a human-mouse chimeric monoclonal antibody directed against the extracellular domain of the EGF receptor (Goldstein et al., 1995; Prewett et al., 1996) . Binding of cetuximab to the receptor blocks ligand-mediated receptor activation and the subsequent signal transduction cascade, leading to inhibition of cell cycle traversal, reduction in tumor angiogenesis, sensitization of cancer cells to conventional chemotherapy and radiotherapy, and induction of apoptosis in certain types of cancer cells that have an innate high sensitivity to EGF receptor blockade or inhibition Baselga, 2000, 2003) . Cetuximab was recently approved for the treatment of patients with irinotecan-refractory colorectal cancers (Cunningham et al., 2004) . In this study, we found that subtoxic doses of perifosine did indeed enhance the antitumor activity of cetuximab in two PTEN-deficient human cancer cell lines, MDA468 breast cancer cells and PC3 prostate cancer cells. Our data therefore support the use of rational combination of alkylphospholipids and cetuximab for the treatment of cancer characterized by PTEN mutations or deletion.
Results
Effect of perifosine on the baseline levels of protein phosphorylation of Akt, p44/42MAPK, SAPK/JNK, and p38MAPK in PTEN-deficient cancer cells MDA468 human breast cancer cells and PC3 human prostate cancer cells, unlike A431 human vulvar squamous carcinoma cells, express no detectable levels of PTEN protein because of the genetic aberrations within the cells (Vlietstra et al., 1998; Lu et al., 1999) . As a result, these cells contain a high level of Akt kinase activity, which is characterized by a high baseline level of phosphorylated Akt (Figure 1a) . We found that these cells show only a moderate 20-30% growth inhibition in response to treatment with the EGF receptor-blocking monoclonal antibody cetuximab, compared with A431 cells in which a 50-60% growth inhibition was achieved by cetuximab treatment (Figure 1b) . To determine whether perifosine may enhance the responses of these PTEN-deficient cancer cells to cetuximab, we first examined the effect of perifosine on the high baseline activity of Akt in these PTEN-deficient cell lines. Western blot analysis data show that perifosine reduced the baseline levels of phosphorylated Akt in both MDA468 and PC3 cells after a 16-h exposure to the (Figure 2b ). As reduced phosphorylation of GSK3 may be caused by inhibition of multiple intracellular kinases in addition to Akt, we performed additional kinase assay using a GSK3 peptide as an in vitro substrate for the Akt that was immunoprecipitated from the cells treated with perifosine or not (Figure 2c ). We found that treatment of these PTEN-deficient cells with perifosine did reduce the high baseline kinase activity of Akt in the cells. In addition to inhibition of Akt, perifosine also had effects on the levels of phosphorylated p44/42MAPK, SAPK/JNK, and p38MAPK in MDA468 and PC3 cells (Figure 3 ). At lower doses (0.5-1 mM), perifosine moderately stimulated the phosphorylation of MAPK, particularly in the PC3 cells, a finding similar to what has been previously observed by others in different cell lines (Ruiter et al., 2002; De Siervi et al., 2004) . At higher doses (>2.5 mM in the PC3 cells and >5 mM in the MDA468 cells), perifosine reduced the levels of phosphorylated p44/42MAPK. In addition, exposure of the cells to perifosine increased the baseline levels of phosphorylated SAPK/JNK in a perifosine dosedependent manner, indicating activation of the pathway (Ruiter et al., 1999) . At higher doses, perifosine (>5 mM in the PC3 cells, and >10 mM in the MDA468 cells) reduced the levels of phosphorylated p38MAPK, which seemed to be partially associated with the downregulation of p38MAPK protein in both cell lines treated with the higher doses.
We compared perifosine with LY294002, a PI3-Kspecific kinase inhibitor, and PD98059, an MEK-specific kinase inhibitor for their effects on relevant signal pathways. For cells with normal PTEN function, exposure to LY294002 within a conventional dose range (5-10 mM) often leads to an efficient inhibition of PI3-K, resulting in a reduced level of phosphorylated Akt ; however, exposure of the PTEN-deficient MDA468 and PC3 cells to such conventional doses of LY294002 (5-10 mM) had almost no effect on the levels of phosphorylated Akt, whereas the cells remain to be sensitive to PD98059 treatment with conventional doses (10 or 20 mM) (Figure 4) . Although the cells are relatively resistant to LY294002-induced inhibition of Akt phosphorylation, they are sensitive to perifosine. Perifosine was able to markedly reduce the baseline levels of both phosphorylated Akt and phosphorylated p44/42MAPK in both cell lines; the PC3 cells appeared to be more sensitive than the MDA468 cells to perifosine treatment.
Antitumor activity of perifosine used alone and in combination with cetuximab On the basis of these results, we next examined the effect of perifosine used alone and in combination with Figure 2 Inhibition of Akt phosphorylation and kinase activity by perifosine treatment in PTEN-deficient cells. In (a), MDA468 and PC3 cells were exposed to increasing concentrations of perifosine overnight (16 h) in culture medium containing 0.5% FBS. After the treatment, the cells were harvested and processed for Western blot analysis using the antibodies directed against total or Ser473-phosphorylated Akt as indicated. In (b, c), MDA468 and PC3 cells were treated with 5 mM perifosine for 16 h or not. Cell lysates were prepared and split for Western blot analysis using the antibodies directed against total or Ser473-phosphorylated Akt, or phosphorylated GSK3 as indicated (b), and for an in vitro kinase assay using GSK3 peptide as a substrate for the Akt immunoprecipitated from the cell lysates (c). Relative fold means the densitometric value of phosphorylated Akt or GSK3 normalized by corresponding densitometric value of Akt protein detected in the cell lysates (a or b) or in the immunoprecipitates (c) under each treatment condition. J p : Phosphorylated.
Perifosine enhances cetuximab/C225 X Li et al cetuximab in MDA468 and PC3 cells on cell proliferation and survival, as well as their effects on the levels of phosphorylated Akt, p44/42MAPK, SAPK/JNK, and p38MAPK after the treatments. MDA468 and PC3 cells were treated with 5 mM perifosine, an effective concentration that produces the most characteristic activities of this agent (Figures 2 and 3) , and 10 nM cetuximab, a receptor-oversaturating concentration of the antibody that has been previously shown to sufficiently block EGF receptor function (Goldstein et al., 1995; Prewett et al., 1996) . Figure 5 showed that the high baseline levels of phosphorylated Akt were minimally affected by cetuximab in MDA468 or PC3 cells, but were markedly reduced by perifosine. This perifosine-mediated inhibition of Akt phosphorylation was moderately further enhanced when the cells were cotreated with cetuximab. The baseline levels of phosphorylated p44/42MAPK were reduced after treatment with either agent, and were further reduced by the combination treatment with cetuximab and perifosine in both MDA468 and PC3 cells ( Figure 5 ). Interestingly, perifosine and cetuximab had opposite effects on the levels of phosphorylated SAPK/JNK: perifosine increased the baseline levels of phosphorylated SAPK/JNK, whereas cetuximab reduced the baseline levels. The combination treatment offset the respective effects of perifosine and cetuximab on the levels of phosphorylated SAPK/JNK such that the levels were minimally changed in both cell lines. In Figure 3 Inhibition of protein phosphorylation of p44/42MAPK and p38MAPK, and elevation of SAPK/JNK phosphorylation by perifosine treatment. MDA468 and PC3 cells were exposed to increasing concentrations of perifosine overnight (16 h) in culture medium containing 0.5% FBS. After the treatment, the cells were harvested and processed for Western blot analysis using the antibodies directed against total or phosphorylation-specific proteins as indicated. Relative fold means the densitometric value of protein phosphorylation normalized by corresponding densitometric value of protein expression under each treatment condition, and the value from untreated cells was taken as unity. The results shown are representative of three independent experiments. The level of b-actin served as the control for equal lysate protein loading in each lane. J p : Phosphorylated.
Figure 4
Comparison of perifosine with LY294002 and PD98059 on inhibiting the levels of phosphorylated Akt and MAPK in PTEN-deficient cells. MDA468 and PC3 cells were exposed to the indicated concentrations of perifosine, LY294002, and PD98059 overnight (16 h) in culture medium containing 0.5% FBS. After the treatment, the cells were harvested and processed for Western blot analysis using the antibodies indicated. Relative fold means the densitometric value of protein phosphorylation normalized by the corresponding densitometric value of b-actin expression under the same experiment condition. The value from untreated cells was taken as unity. The results shown are representative of three independent experiments. J p : Phosphorylated.
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X Li et al contrast to the changes in the levels of phosphorylated SAPK/JNK, treatment with perifosine reduced the levels of p38MAPK, an effect probably compounded by the downregulation of p38MAPK induced by perifosine in both MDA468 and PC3 cells, particularly in the PC3 cells. Perifosine itself has strong dose-dependent cytotoxic activity in both MDA468 and PC3 cells. At concentrations ranging from 0.625 to 10 mM, a 72-h continuous exposure of the MDA468 and PC3 cells to perifosine led to a marked dose-dependent growth inhibition of the cells (Figure 6a ), as measured by the MTT assay. The addition of cetuximab enhanced the antiproliferative effect of perifosine in both cell lines, shown by a downward shift of perifosine dose-cell survival curve in both cell lines (Figure 6a ). Analysis of variance (ANOVA), which was used to produce regression estimates and to analyse the difference of variance between the groups, indicates that the enhancements were statistically significant in both cell lines (Po0.05).
As with the effects of many chemotherapeutic drugs with different mechanisms of action, the potent cytotoxicity of perifosine at high doses may cause unwanted side effects to normal cells when the agent is tested in vivo. This is, in fact, a part of rationale for combining two or more agents at lower doses that act on either the same or complementary targets or pathways to enhance antitumor activity and/or reduce side effects. To examine the extent to which the antiproliferative activity of cetuximab may be enhanced by a subtoxic dose of perifosine, we cultured the MDA468 and PC3 cells with increasing concentrations of cetuximab, from 1.25 to 20 nM, for 5 days with or without concomitant treatment with subtoxic doses of perifosine (1.5 mM for MDA468 and 1 mM for PC3) (Figure 6b ). Compared with the results of the cetuximab treatment alone, which produced a maximum of 20-30% growth inhibition irrespective of cetuximab doses used (the highest dose used was 200 nM, data not shown) in both cell lines, the combination treatment with the subtoxic dose of perifosine enhanced the growth inhibition of the cells after treatment with cetuximab. Statistical analysis with ANOVA indicates that the enhancements were also significant in both cell lines (Po0.05).
We further examined the effects of combination treatment of perifosine and cetuximab on the induction of apoptosis in the MDA468 and PC3 cells with two independent measures (for the levels of histoneassociated DNA fragments in the cytoplasm by enzyme-linked immunosorbent assay (ELISA), and the levels of PARP cleavage by Western blot analysis). A 16-h exposure of the cells to 10 nM cetuximab had no effect on the induction of apoptosis, but an induction of apoptosis was detected in the cells after they were exposed for 16 h to 5 mM perifosine (Figure 7a ). The perifosine-induced apoptosis was increased when the cells were treated with the perifosine and cetuximab combination. Student's t-test analyses were used to assess the statistical differences in the levels of apoptosis induced by single treatment (perifosine or cetuximab) and by the combination treatment. The results are statistically significant between the either single treat- Perifosine enhances cetuximab/C225 X Li et al ment and the combination treatment in both cell lines. The enhanced induction of apoptosis was further confirmed by Western blot analysis detecting the cleavage of PARP induced by the treatments (Figure 7b ). The levels of cleaved PARP were much higher in both MDA468 and PC3 cells after the perifosine and cetuximab combination treatment than after the perifosine treatment alone. Taken together with the data shown in Figures 6 and 7 , these results suggest that there is clearly an enhancement of antitumor activity when perifosine and cetuximab were used in combination.
To determine whether perifosine used either alone or in combination with cetuximab has similar activity in inhibiting Akt phosphorylation in cells with wild-type PTEN, A431 cells were transfected with either the wildtype Akt, a myristoylated Akt, or a dominant-negative Akt, followed by exposure of the transfected cells to perifosine or cetuximab treatment as described for MDA468 and PC3 cells. We found that perifosine or cetuximab markedly reduced the level of phosphorylated wild-type Akt, but neither agent was effective on reducing the level of myristoylation-induced phosphorylation of Akt (Figure 8 ). This observation suggested that perifosine may only reduce the phosphorylation of Akt mediated by increased levels of PIP3. Perifosine has no effect on the phosphorylation of Akt that is PIPindependent, such as the phosphorylation of Akt induced by myristoylation.
Roles of Akt inhibition and SAPK/JNK activation in perifosine-mediated cytotoxicity
Recent studies have suggested a possible cross-talk between the PI3-K/Akt and SAPK/JNK pathways (Gratton et al., 2001; Aikin et al., 2004; Gonzalez et al., 2004) . Akt can regulate several proteins known to suppress the JNK pathway, including MLK3 (Barthwal et al., 2003) , JNK-interacting protein 1 , and MKK4 (Park et al., 2002) . Akt, in particular, was found to directly phosphorylate ASK1, leading to the suppression of JNK signaling (Kim et al., 2001) . To address whether the activation of SAPK/JNK as well as inhibition of p44/42MAPK and p38MAPK after perifosine treatment are dependent on the inhibition of Akt by perifosine, we first examined whether the LY294002-mediated inhibition of Akt had similar effects on the levels of SAPK/JNK, p44/42MAPK, 
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X Li et al and p38MAPK phosphorylation. Owing to the PTEN deficiency in MDA468 and PC3 cells, a relatively high dose of LY294002 (20 mM) was used, which produced a moderate inhibitory effect on the levels of phosphorylated Akt in MDA468 cells and a marked inhibitory effect in the PC3 cells (Figure 9a ). At 40 mM, the action of LY294002 became nonspecific because the levels of phosphorylated MAPK were also markedly affected; however, there was no similar increase in the level of phosphorylated SAPK/JNK found in the cells after perifosine treatment. This observation suggests that inhibition of PI3-K/Akt does not necessarily lead to an increased phosphorylation of SAPK/JNK in these cells.
To further address this question, we examined the PC3 cells that were transiently transfected with the pcDNA3.1 control vector or the vector constructed with the wild-type Akt, a myristoylated Akt, or a dominantnegative Akt (Figure 9b ). Similar to the findings with A431 cells, perifosine failed to reduce the level of myristoylation-mediated phosphorylation of Akt in the PC3 cells, but successfully reduced the levels of Akt phosphorylation in the cells transfected with either the control vector, wild-type Akt, or a dominant-negative Akt. However, regardless of the results of Akt phosphorylation inhibition by perifosine in the cells, the SAPK/JNK phosphorylation is always increased and MAPK phosphorylation is always reduced. This finding strongly suggested that the inhibition of phosphorylation of Akt and MAPK and elevation of phosphorylation of SAPK/JNK are independent when the cells responded to perifosine treatment. In contrast, the phosphorylation of p38MAPK appears to be correlated with the activation status of Akt, because perifosine failed to reduce the level of phosphorylated p38MAPK in the cells transfected with the myristoylated Akt. In cells expressing the dominant-negative Akt, the baseline level of phosphorylated p38MAPK was also lower.
Discussion
In this study, we examined the activity of perifosine alone and in combination with cetuximab in two PTENdeficient human cancer cell lines, MDA468 breast cancer cells that contain mutated PTEN (Lu et al., 1999) and PC3 prostate cancer cells that are PTEN-null (Vlietstra et al., 1998) . When used alone, perifosine showed a dose-dependent antiproliferative and apoptosisinducing activity in both cell lines, and, when combined at a subtoxic dose with cetuximab, perifosine enhanced the responses of MDA468 and PC3 to cetuximab treatment.
Perifosine appears to be a multi-target agent that directly affects the signal transduction pathways involving at least Akt, MAPK, and SAPK/JNK, whereas cetuximab blocks EGF receptor-mediated signal Figure 7 Induction of apoptosis by perifosine alone and in combination with cetuximab in MDA468 and PC3 cells. MDA468 and PC3 cells were treated with 5 mM perifosine, 10 nM cetuximab, or a combination of the two overnight (16 h) in medium containing 0.5% FBS. The cells were then harvested and prepared for an apoptosis ELISA assay detecting histone-associated DNA fragment in the cytoplasm (a) and for the Western blot analysis detecting PARP cleavage using specific antibodies (b). Student's t-test statistical analysis was undertaken with Intercooled Stata 8.0 statistical software package, and the P-values of comparison between two indicated groups are shown. Figure 8 Effects of perifosine and cetuximab used alone and in combination on the levels of Akt phosphorylation. A431 cells were transiently transfected with the pcDNA3.1 control vector, or the vector containing the wild-type Akt, a myristoylated Akt, or a dominant-negative Akt (Akt-K179A/T308A/S473A) for 16 h. The cells were then cultured for an additional 24 h in transfection reagent-free medium prior to exposure to 5 mM perifosine, 10 nM cetuximab, or a combination of the two, respectively, overnight (16 h) in medium containing 0.5% FBS. The cells were then harvested and prepared for Western blot analysis with antibodies directed against total or Ser473-phosphorylated Akt. J p : Phosphorylated.
Perifosine enhances cetuximab/C225 X Li et al transduction, thereby inhibiting multiple downstream pathways, including the Akt, MAPK, and SAPK/JNK pathways. Among the potential targets of perifosine that we examined, Akt was the most sensitive target; a reduction in the levels of phosphorylated Akt was detected in the cells after they were exposed to perifosine at concentrations greater than 2.5 mM for the MDA468 cells and greater than 1 mM for PC3 cells. Our data as well as the data from others suggest that perifosine reduces the level of Akt phosphorylation by disturbing the phosphatidylinositol-mediated recruitment of pleckstrin homology domain-containing molecules, including Akt, to the membrane proximity for phosphorylation (Kondapaka et al., 2003) . This was because perifosine did not affect the phosphorylation of myristoylated Akt, which can anchor to the membrane in a phosphatidylinositol-independent fashion. The failure of perifosine to inhibit the phosphorylation of myristoylated Akt was not due to a high expression level of the protein because the wild-type Akt had a comparable high expression level, but was still sensitive to the treatment by perifosine. The effect of perifosine on the reduction of Akt phosphorylation was the rationale that prompted us to explore the effect of combining perifosine and cetuximab on the MDA468 and PC3 cells, because cetuximab had failed to reduce Akt phosphorylation in these cells, a fact that has been attributed to the dysfunction of PTEN in these cells in the studies of treatment by the EGF receptor tyrosine kinase inhibitor gefitinib (Bianco et al., 2003; She et al., 2003) .
It took higher concentrations of perifosine to reduce the levels of phosphorylated MAPK than that of phosphorylated Akt. A marked inhibition of MAPK phosphorylation was observed at concentrations of perifosine greater than 5 mM in the MDA468 cells and 2.5 mM in the PC3 cells. Previous studies have shown that the exposure of certain types of cells to lower concentrations of perifosine paradoxically stimulated the levels of phosphorylated MAPK, whereas exposure to high concentrations of perifosine reduced the levels of phosphorylated MAPK (Ruiter et al., 2002; De Siervi et al., 2004) . Similarly, in our study, we found a slight increase in the levels of phosphorylated MAPK after the cells were exposed to 0.5-1 mM perifosine for the MDA468 cells and 0.25-0.5 mM perifosine for the PC3 cells (Figure 2) . However, the increase in the levels of phosphorylated MAPK was found not to be mitogenic (Ruiter et al., 2002) . Others also found a similar increase in the level of phosphorylated Akt in cells exposed to low concentrations of perifosine (Ruiter et al., 1999) ; however, we did not observe such a change in our study, probably because of the difference in the cell lines used Perifosine enhances cetuximab/C225 X Li et al and the fact that the concentration ranges used by the others were generally lower than those we used in the current study (Ruiter et al., 2002) . We found the effects of perifosine and cetuximab on the MAPK pathway to be additive as both treatments resulted in lower levels of phosphorylated MAPK. The SAPK/JNK pathway, which is mainly activated by cellular stresses, plays an important role in mediating the induction of apoptosis. Previous studies have suggested that activation of the SAPK/JNK pathway is essential for perifosine-induced apoptosis because expression of a dominant-negative form of c-jun, a substrate of SAPK/JNK, nullified the apoptosisinducing activity of perifosine (Ruiter et al., 1999) . This conclusion would have been stronger if a dominantnegative SAPK/JNK had been used in that study. In our study, exposure of the cells to perifosine led to increased levels of phosphorylated SAPK/JNK in both cell lines; the PC3 cells were more sensitive than the MDA468 cells to the increase. Intriguingly, while perifosine increased the levels of SAPK/JNK phosphorylation, cetuximab reduced the levels of phosphorylation. Their effects on the levels of SAPK/JNK phosphorylation were offset by the perifosine and cetuximab combination treatment of the cells; however, the biological consequences of the combination treatment resulted in an enhancement rather an antagonism of the antiproliferative and antisurvival effects on both cell lines. This finding raises an important question as to the exact role that SAPK/ JNK plays in perifosine-induced antitumor activity.
Another related and interesting question is whether the enhanced antitumor activity that results from the combination treatment occurs only in PTEN-deficient cells. In our preliminary experiments, we tested the effect of perifosine and cetuximab combination on cell proliferation and survival by MTT assays in A431 cells that contain wild-type PTEN (shown in Figure 1 ). We found no enhanced antiproliferative effect or even slightly reduced effect in several repeated experiments by the combination treatment with cetuximab and perifosine in cell culture (data not shown). As a caveat, however, in PTEN wild-type cells, the basal levels of phosphorylated Akt are much lower than the levels in PTEN-deficient cells, and the basal levels of phosphorylated Akt were markedly reduced after cetuximab treatment. A431 cells themselves are quite sensitive to cetuximab treatment alone. These facts may explain the lack of benefit from adding perifosine to the cetuximab treatment in A431 cells. If the combination treatment leads to enhanced antiproliferative effects only in PTEN-deficient cancer cells, not in PTEN wild-type cells, or even if it leads to reduced effects of the combination treatment in the PTEN wild-type cells, this scenario might, in fact, provide a selectivity of the combination treatment, which could be important clinically because potential side effects, presumably caused by activation of SAPK/JNK by perifosine in normal cells, might be alleviated by combining perifosine with cetuximab.
Depending on the cell type and the context of cell signaling, an increase in the level of phosphorylated p38MAPK may lead either to mitogenesis or to apoptosis. In our studies, exposure of both MDA468 and PC3 cells to perifosine led to a decrease not only in the level of p38MAPK phosphorylation but also in the total level of the protein. Furthermore, these changes correlated with the phosphorylation level of Akt because expression of the myristoylated Akt abolished the effect of perifosine to reduce phosphorylated p38MAPK levels. In addition, the expression of a dominantnegative form of Akt reduced the level of phosphorylated p38MAPK, and exposure of the cells expressing dominant-negative Akt to perifosine failed to further decrease phosphorylated p38MAPK levels. The pattern of the response of phosphorylated p38MAPK to treatment by cetuximab alone or in combination with perifosine was similar to the pattern of Akt to the same treatments.
In conclusion, our data from the signal transduction studies and the in vitro cell culture experiments strongly suggest that perifosine enhances the antitumor activity of cetuximab in cancer cells with PTEN mutation or deletion. A question remains whether the counterbalancing effects of perifosine and cetuximab on the levels of phosphorylated SAPK/JNK play any role in the selectivity of the antiproliferative effects of this combination treatment on PTEN-deficient cancer cells and PTEN wild-type cells, including normal cells. Experiments conducted in the cells engineered to stably express a myristoylated Akt may help to answer the question. 
Materials and methods

Reagents
Cell lines and culture
The MDA468 breast cancer cells and PC3 prostate cancer cells were originally purchased from the American Type Culture Collection (Manassas, VA, USA). The cells were grown and routinely maintained in Dulbecco's modified Eagle's medium/ F12 medium supplemented with 10% fetal bovine serum (FBS), 2 mM glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin. They were incubated in a 371C humidified atmosphere (95% air and 5% CO 2 ).
Western blot analysis and blotting antibodies After receiving various treatments described in the figure legends, the cells cultured in 60-mm dishes were harvested with a rubber scraper, and then washed two times with cold phosphate-buffered saline (PBS). The cell pellets were lysed and left on ice for a minimum of 10 min with a buffer containing 50 mM Tris, pH 7.4, 150 mM NaCl, 0.5% NP-40, 50 mM NaF, 1 mM Na 3 VO 4 , 1mM phenylmethylsulfonyl fluoride, 25 mg/ml leupeptin, and 25 mg/ml aprotinin. The lysates were then cleared by centrifugation, and the supernatants were collected. Equal amounts of lysate protein were separated by SDS-polyacrylamide gel electrophoresis, followed by Western blot analysis with various primary antibodies described in figure legends. Specific signals were visualized using the enhanced chemiluminescence detection kit (Amersham, Arlington Heights, IL, USA).
Akt kinase assay A nonradioactive Akt in vitro kinase assay was performed by incubating a GSK3 fusion protein (used as the substrate, 1 mg/ assay; Cell Signaling Technology) with the Akt proteins (served as the kinase) that were immunoprecipitated with corresponding anti-tag antibodies from the lysates of the cells transfected with various Akt expression vectors in the presence of 33.3 mM unlabeled ATP for 30 min at 301C in a total volume of 30 ml/assay. The products of the kinase reaction were resolved by SDS-PAGE, followed by Western blot analysis with the phospho-GSK3a/b (Ser-21/9) antibody.
MTT colorimetric assay for cell survival and proliferation
The assays were conducted in 24-well culture plates containing 0.5 ml of medium/well. Cells were allowed to attach to the plates overnight prior to treatments described in the figure legend. Cell viability were assessed by incubating the cells for 2 h at 371C in a CO 2 incubator with 50 ml/well of 10 mg/ml 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) (Sigma-Aldrich, St Louis, MO, USA). The cells were lysed with 500 ml/well of lysis buffer containing 20% SDS in dimethylformamide/H 2 O (1:1, v/v), pH 4.7, at a 371C oven for at least 6 h or more. The cell lysates were measured for optical absorbance at a wavelength of 595 nm. The relative number of viable cells was expressed as a percentage of the optical absorbance value in relation to the optical absorbance value of the corresponding control or untreated cells.
Quantification of apoptosis by enzyme-linked immunosorbent assay An ELISA kit (Roche Diagnostics Corp., Indianapolis, IN, USA) that quantitatively measures cytoplasmic histoneassociated DNA fragments (mononucleosomes and oligonucleosomes) during apoptosis was used as we reported previously to quantify the extent of apoptosis (Liu et al., 2000) .
cDNA construct and transient expression The pcDNA3.1 expression vectors containing the wild-type Akt, a myristoylated Akt1, or dominant-negative form of Akt (K179A/T308A/S473A) were previously described (Knuefermann et al., 2003; Liang et al., 2003) . Transient transfection was performed with the Lipofectamine 2000 (LF2000) transfection kit, according to the manufacturer's instructions (Invitrogen Corp., Carlsbad, CA, USA).
Statistical analysis
All statistical analyses were carried out with the Intercooled Stata 8.0 statistical software package (StataCorp, College Station, TX, USA).
Abbreviations
EGF, epidermal growth factor; PTEN, phosphatase and tensin homologue deleted on chromosome 10; PI3-K, phosphoinositide 3-kinase; PIP, phosphatidylinositol phosphate; MAPK, mitogen-activated protein kinase; SAPK, stress-activated protein kinase; JNK, c-jun NH 2 -terminal kinase; FBS, fetal bovine serum; PBS, phosphate-buffered saline.
